Mittendorf, Kathleen F. http://orcid.org/0000-0003-1097-9171
Ukaegbu, Chinedu
Gilmore, Marian J.
Lindberg, Nangel M.
Kauffman, Tia L.
Eubanks, Donna J.
Shuster, Elizabeth
Allen, Jake
McMullen, Carmit
Feigelson, Heather Spencer
Anderson, Katherine P.
Leo, Michael C.
Hunter, Jessica Ezzell
Sasaki, Sonia Okuyama
Zepp, Jamilyn M.
Syngal, Sapna
Wilfond, Benjamin S.
Goddard, Katrina A. B.
Funding for this research was provided by:
National Human Genome Research Institute (UM1HG007292)
National Cancer Institute (R01CA132829)
Article History
Received: 30 October 2020
Accepted: 4 March 2021
First Online: 23 March 2021
Compliance with ethical standards
:
: PREMM® and all associated logos are trademarks™ or registered® trademarks of Dana Farber Cancer Institute, Inc. Dr. Syngal has served as a consultant for Myriad Genetics and DC Health Technologies, and has rights to an inventor portion of the licensing revenue from PREMM®<sub>5</sub>.All other authors report no conflict of interest.
: The KPNW Institutional Review Board (IRB) approved this study and all collaborating IRBs ceded to KPNW except Dana Farber Cancer Institute and Columbia University, who approved the study separately.
: All study participants provided informed consent prior to study enrollment.